CA3229752A1 - Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action - Google Patents
Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action Download PDFInfo
- Publication number
- CA3229752A1 CA3229752A1 CA3229752A CA3229752A CA3229752A1 CA 3229752 A1 CA3229752 A1 CA 3229752A1 CA 3229752 A CA3229752 A CA 3229752A CA 3229752 A CA3229752 A CA 3229752A CA 3229752 A1 CA3229752 A1 CA 3229752A1
- Authority
- CA
- Canada
- Prior art keywords
- substituent group
- hydrogen
- optionally substituted
- group
- alkyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/66—Phosphorus compounds
- A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07F—ACYCLIC, CARBOCYCLIC OR HETEROCYCLIC COMPOUNDS CONTAINING ELEMENTS OTHER THAN CARBON, HYDROGEN, HALOGEN, OXYGEN, NITROGEN, SULFUR, SELENIUM OR TELLURIUM
- C07F9/00—Compounds containing elements of Groups 5 or 15 of the Periodic Table
- C07F9/02—Phosphorus compounds
- C07F9/547—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom
- C07F9/6561—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings
- C07F9/65616—Heterocyclic compounds, e.g. containing phosphorus as a ring hetero atom containing systems of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring or ring system, with or without other non-condensed hetero rings containing the ring system having three or more than three double bonds between ring members or between ring members and non-ring members, e.g. purine or analogs
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Virology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Oncology (AREA)
- General Chemical & Material Sciences (AREA)
- Communicable Diseases (AREA)
- Epidemiology (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Pulmonology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Saccharide Compounds (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| JP2021134801 | 2021-08-20 | ||
| JP2021-134801 | 2021-08-20 | ||
| PCT/JP2022/031308 WO2023022216A1 (ja) | 2021-08-20 | 2022-08-19 | ウイルス増殖抑制作用を有するヌクレオシド誘導体及びそれらのプロドラッグ |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| CA3229752A1 true CA3229752A1 (en) | 2023-02-23 |
Family
ID=85240607
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| CA3229752A Pending CA3229752A1 (en) | 2021-08-20 | 2022-08-19 | Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action |
Country Status (13)
Families Citing this family (7)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JP7559223B2 (ja) | 2020-08-24 | 2024-10-01 | ギリアード サイエンシーズ, インコーポレイテッド | リン脂質化合物及びその使用 |
| US11926645B2 (en) | 2020-08-27 | 2024-03-12 | Gilead Sciences, Inc. | Compounds and methods for treatment of viral infections |
| TWI925033B (zh) | 2020-10-16 | 2026-05-11 | 美商基利科學股份有限公司 | 磷脂化合物及其用途 |
| KR20240154647A (ko) | 2022-03-02 | 2024-10-25 | 길리애드 사이언시즈, 인코포레이티드 | 바이러스성 감염 치료를 위한 화합물 및 방법 |
| EP4547665A1 (en) | 2022-06-30 | 2025-05-07 | Gilead Sciences, Inc. | Solid forms of a nucleoside analogue and uses thereof |
| US12357577B1 (en) | 2024-02-02 | 2025-07-15 | Gilead Sciences, Inc. | Pharmaceutical formulations and uses thereof |
| WO2026160341A1 (ja) * | 2025-01-21 | 2026-07-30 | 塩野義製薬株式会社 | ウイルス感染治療用アザ糖誘導体 |
Family Cites Families (33)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| EP0071227B1 (en) | 1981-07-31 | 1987-11-11 | Sloan-Kettering Institute For Cancer Research | Anti-leukemic beta-glycosyl c-nucleosides |
| US5985848A (en) | 1997-10-14 | 1999-11-16 | Albert Einstein College Of Medicine Of Yeshiva University | Inhibitors of nucleoside metabolism |
| WO2002018371A1 (en) | 2000-08-29 | 2002-03-07 | Industrial Research Limited | Nucleoside metabolism inhibitors |
| US7098334B2 (en) | 2002-03-25 | 2006-08-29 | Industrial Research Limited | 4-amino-5H-pyrrolo[3,2-d]pyrimidine inhibitors of nucleoside phosphorylases and nucleosidases |
| BR0309581A (pt) | 2002-05-06 | 2005-03-29 | Genelabs Tech Inc | Derivados de nucleosìdeo para tratamento de infecção por vìrus de hepatite c |
| SG182849A1 (en) | 2003-04-25 | 2012-08-30 | Gilead Sciences Inc | Antiviral phosphonate analogs |
| WO2005123087A2 (en) | 2004-06-15 | 2005-12-29 | Merck & Co., Inc. | C-purine nucleoside analogs as inhibitors of rna-dependent rna viral polymerase |
| US7560434B2 (en) | 2004-06-22 | 2009-07-14 | Biocryst Pharmaceuticals, Inc. | AZA nucleosides, preparation thereof and use as inhibitors of RNA viral polymerases |
| AU2005302448B2 (en) | 2004-10-29 | 2012-07-19 | Biocryst Pharmaceuticals, Inc. | Therapeutic furopyrimidines and thienopyrimidines |
| WO2007069924A1 (en) | 2005-12-15 | 2007-06-21 | Industrial Research Limited | Deazapurine analogs of 4'-aza-l-nucleosides |
| NZ598927A (en) | 2007-01-12 | 2013-09-27 | Biocryst Pharm Inc | Antiviral nucleoside analogs |
| DK2155758T3 (da) | 2007-05-10 | 2012-11-05 | Biocryst Pharm Inc | Tetrahydrofuro[3,4-d]dioxolanforbindelser til anvendelse i behandlingen af virusinfektioner og cancer |
| EP2313102A2 (en) | 2008-07-03 | 2011-04-27 | Biota Scientific Management | Bycyclic nucleosides and nucleotides as therapeutic agents |
| TW201305185A (zh) | 2010-09-13 | 2013-02-01 | 吉李德科學股份有限公司 | 用於抗病毒治療之2’-氟取代之碳-核苷類似物 |
| US9290501B2 (en) | 2010-11-29 | 2016-03-22 | Albert Einstein College Of Medicine, Inc. | Methods, assays and compounds for treating bacterial infections by inhibiting methylthioinosine phosphorylase |
| NZ629996A (en) * | 2012-03-13 | 2016-10-28 | Gilead Sciences Inc | 2’- substituted carba-nucleoside analogs for antiviral treatment |
| AR090699A1 (es) | 2012-04-18 | 2014-12-03 | Biocryst Pharm Inc | Compuestos inhibidores de la actividad de la arn polimerasa viral |
| WO2014035140A2 (en) | 2012-08-30 | 2014-03-06 | Kainos Medicine, Inc. | Compounds and compositions for modulating histone methyltransferase activity |
| WO2014093924A1 (en) | 2012-12-13 | 2014-06-19 | Moderna Therapeutics, Inc. | Modified nucleic acid molecules and uses thereof |
| MX2015005949A (es) * | 2012-11-16 | 2015-09-08 | Biocryst Pharm Inc | Nucleosidos que contienen aza-azucar antiviral. |
| AU2014265483B2 (en) | 2013-05-14 | 2018-08-02 | Biocryst Pharmaceuticals, Inc. | Anti-influenza compositions and methods |
| UA119050C2 (uk) | 2013-11-11 | 2019-04-25 | Ґілеад Саєнсиз, Інк. | ПІРОЛО[1.2-f][1.2.4]ТРИАЗИНИ, ЯКІ ВИКОРИСТОВУЮТЬСЯ ДЛЯ ЛІКУВАННЯ РЕСПІРАТОРНО-СИНЦИТІАЛЬНИХ ВІРУСНИХ ІНФЕКЦІЙ |
| WO2015143712A1 (en) | 2014-03-28 | 2015-10-01 | Merck Sharp & Dohme Corp. | 4'-substituted nucleoside reverse transcriptase inhibitors |
| TWI698444B (zh) | 2014-10-29 | 2020-07-11 | 美商基利科學股份有限公司 | 製備核糖苷的方法 |
| CA2966033A1 (en) | 2014-10-31 | 2016-05-06 | Cocrystal Pharma, Inc. | 2',2'-dihalo nucleoside analogs for treatment of the flaviviridae family of viruses and cancer |
| JPWO2018199048A1 (ja) | 2017-04-25 | 2020-05-07 | 大原薬品工業株式会社 | ヌクレオシド系抗がん剤または抗ウィルス剤の5’位モノ燐酸ジベンジルエステル誘導体 |
| WO2018230479A1 (ja) | 2017-06-13 | 2018-12-20 | 大原薬品工業株式会社 | ヌクレオシド系抗がん剤又は抗ウィルス剤の5'位シリルエーテル誘導体 |
| WO2019053696A1 (en) * | 2017-09-18 | 2019-03-21 | Alios Biopharma, Inc. | SUBSTITUTED NUCLEOSIDES, NUCLEOTIDES AND ANALOGS THEREOF |
| EP3737359A4 (en) | 2018-01-12 | 2021-11-03 | Board of Regents of the University of Nebraska | ANTIVIRAL PRODRUGS AND THEIR FORMULATIONS |
| WO2021040356A1 (en) | 2019-08-23 | 2021-03-04 | Kainos Medicine, Inc. | C-nucleosides, c-nucleotides and their analogs, equivalents and prodrugs thereof for ectonucleotidase inhibition |
| CN112778310B (zh) | 2020-04-20 | 2025-05-30 | 中国科学院上海药物研究所 | 核苷类似物或含有核苷类似物的组合制剂在抗病毒中的应用 |
| CN112062800B (zh) | 2020-09-02 | 2022-11-18 | 广东东阳光药业有限公司 | 核苷化合物的氨基磷酸酯衍生物及其用途 |
| CN112010916B (zh) | 2020-09-09 | 2022-12-27 | 广东东阳光药业有限公司 | 核苷化合物的氨基磷酸酯衍生物及其用途 |
-
2022
- 2022-08-19 IL IL310854A patent/IL310854A/en unknown
- 2022-08-19 US US18/684,486 patent/US20250170155A1/en active Pending
- 2022-08-19 CA CA3229752A patent/CA3229752A1/en active Pending
- 2022-08-19 JP JP2023542451A patent/JPWO2023022216A1/ja active Pending
- 2022-08-19 MX MX2024002116A patent/MX2024002116A/es unknown
- 2022-08-19 WO PCT/JP2022/031308 patent/WO2023022216A1/ja not_active Ceased
- 2022-08-19 PE PE2024000272A patent/PE20240654A1/es unknown
- 2022-08-19 CN CN202280069993.0A patent/CN118119624A/zh active Pending
- 2022-08-19 EP EP22858533.7A patent/EP4389750A4/en active Pending
- 2022-08-19 KR KR1020247008024A patent/KR20240050362A/ko active Pending
- 2022-08-19 AU AU2022331233A patent/AU2022331233A1/en active Pending
-
2024
- 2024-02-09 ZA ZA2024/01270A patent/ZA202401270B/en unknown
- 2024-03-13 CO CONC2024/0003018A patent/CO2024003018A2/es unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA202401270B (en) | 2026-05-27 |
| MX2024002116A (es) | 2024-03-06 |
| EP4389750A1 (en) | 2024-06-26 |
| CO2024003018A2 (es) | 2024-03-18 |
| PE20240654A1 (es) | 2024-04-04 |
| AU2022331233A1 (en) | 2024-02-29 |
| JPWO2023022216A1 (cg-RX-API-DMAC7.html) | 2023-02-23 |
| KR20240050362A (ko) | 2024-04-18 |
| IL310854A (en) | 2024-04-01 |
| WO2023022216A1 (ja) | 2023-02-23 |
| US20250170155A1 (en) | 2025-05-29 |
| EP4389750A4 (en) | 2025-10-01 |
| CN118119624A (zh) | 2024-05-31 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AU2022331233A1 (en) | Nucleoside derivatives and prodrugs thereof having viral growth inhibitory action | |
| EP4185569B1 (en) | Methods and compositions for targeting pd-l1 | |
| CA2943220C (en) | Benzimidazole derivatives as erbb tyrosine kinase inhibitors for the treatment of cancer | |
| EP2867232B1 (en) | 5-azaindazole compounds and methods of use | |
| EP4004002B1 (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| CA3170503A1 (en) | Stat degraders and uses thereof | |
| US12508264B2 (en) | Quinazoline compounds, preparation method, use, and pharmaceutical composition thereof | |
| CA3078267A1 (en) | Compositions and methods of modulating the immune response by activating alpha protein kinase 1 | |
| WO2016174079A1 (en) | Rsv antiviral pyrazolo- and triazolo-pyrimidine compounds | |
| BR112020002736A2 (pt) | inibidores seletivos da proteína arginina metiltransferase 5 (prmt5) | |
| CA3104088A1 (en) | Ectonucleotidase inhibitors and methods of use thereof | |
| AU2021224588B2 (en) | Antiviral compounds | |
| WO2021214136A1 (en) | Rsv inhibiting 3-substituted quinoline and cinnoline derivatives | |
| CN106589055A (zh) | 取代的细胞酰二肽类化合物及其制备方法和用途 | |
| CA3223728A1 (en) | Aromatic compound, pharmaceutical composition, and application thereof | |
| WO2024054954A1 (en) | Heterobifunctional compounds and methods of treating disease | |
| EP3044225B1 (en) | Tricyclic gyrase inhibitors | |
| IL302458B2 (en) | Derivative of an amide with antiviral activity | |
| TWI901793B (zh) | 多功能環二核苷酸及其用途 | |
| TW202517253A (zh) | Cdk2抑制劑及其用途 | |
| HK40079070B (zh) | 多功能环二核苷酸及其用途 | |
| CN102766165A (zh) | 合成钼蝶呤前体z衍生物的方法 | |
| HK40074766B (en) | Macrocyclic compounds as sting agonists and methods and uses thereof | |
| HK40074766A (en) | Macrocyclic compounds as sting agonists and methods and uses thereof |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD Year of fee payment: 3 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20250702 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20250702 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D11-D117 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION RECEIVED Effective date: 20260721 |
|
| W00 | Other event occurred |
Free format text: ST27 STATUS EVENT CODE: A-1-1-W10-W00-W111 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: CORRESPONDENT DETERMINED COMPLIANT Effective date: 20260721 |
|
| MFA | Maintenance fee for application paid |
Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 4TH ANNIV.) - STANDARD Year of fee payment: 4 |
|
| U00 | Fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED Effective date: 20260724 |
|
| U11 | Full renewal or maintenance fee paid |
Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL Effective date: 20260724 |
|
| D00 | Search and/or examination requested or commenced |
Free format text: ST27 STATUS EVENT CODE: A-1-1-D10-D00-D118 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: REQUEST FOR EXAMINATION REQUIREMENTS DETERMINED COMPLIANT Effective date: 20260806 |
|
| D11 | Substantive examination requested |
Free format text: ST27 STATUS EVENT CODE: A-1-2-D10-D11-D155 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: ALL REQUIREMENTS FOR EXAMINATION DETERMINED COMPLIANT Effective date: 20260806 |